Maravai Lifesciences Holdings, INC

Maravai LifeSciences Holdings, Inc. announced the refinancing of its credit agreement, establishing a new $180 million facility and extending its term loan maturity to June 2032.

Maravai LifeSciences shareholders re-elected three directors and ratified the appointment of Deloitte & Touche LLP at the 2026 Annual Meeting.

Maravai LifeSciences announced first quarter 2026 financial results, showing a 40.5% revenue increase to $65.8 million, a significant improvement in net loss, and positive free cash flow, leading to raised full-year guidance.

Maravai LifeSciences exceeded Q4 revenue expectations and returned to positive Adjusted EBITDA, guiding for 2026 revenue of $200M-$210M.

Maravai LifeSciences reported a net loss of $45.1 million and a 39.7% revenue decrease to $41.6 million in Q3 2025, driven by lower Nucleic Acid Production sales, while Biologics Safety Testing showed growth.

Maravai LifeSciences announced three voluntary board resignations and a reduction in board size to streamline governance and cut administrative expenses.

Maravai LifeSciences Holdings, Inc. reported a significant revenue decrease and negative Adjusted EBITDA for Q3 and the first nine months of 2025, driven by a lack of high-volume vaccine program orders and a challenging R&D funding environment.

Maravai LifeSciences reported a significant decline in revenue and a substantial net loss for Q2 2025, alongside a major workforce reduction and goodwill impairments.

Maravai LifeSciences experienced a significant drop in revenue and reported a net loss for Q1 2025, primarily due to decreased demand for CleanCap used in commercial phase vaccine programs and lower demand for research and discovery products.

Maravai LifeSciences reported its Q3 2024 results, which included a significant goodwill impairment charge and a decrease in revenue, particularly in its Nucleic Acid Production segment.

Maravai LifeSciences reported a revenue increase in Q2 2024, but also a net loss, reflecting ongoing market challenges and strategic adjustments.

Maravai LifeSciences experienced a decrease in revenue during the first quarter of 2024, primarily due to reduced demand in its Nucleic Acid Production segment.

Maravai LifeSciences reported a significant revenue decrease and net loss in 2025, driven by reduced CleanCap sales and substantial impairment charges, while implementing a major corporate realignment.

Maravai LifeSciences Holdings details its financial performance for 2024, highlighting challenges and strategic moves including acquisitions to bolster its nucleic acid production capabilities.

Maravai LifeSciences Holdings, Inc. outlines its share structure, voting rights, and corporate governance policies in its latest 10-K filing, emphasizing anti-takeover provisions and management control.

Rajesh Asarpota, Chief Financial Officer of Maravai Lifesciences Holdings, Inc., reported a transaction in 5,465 shares of common stock on July 30, 2026.

Bernd Brust, CEO of Maravai Lifesciences Holdings, Inc., reported transactions involving Class A Common Stock, including shares withheld for tax obligations.

Rajesh Asarpota, Chief Financial Officer of Maravai Lifesciences Holdings, Inc., reported a transaction involving the withholding of shares to cover tax obligations.

Maravai LifeSciences CEO Bernd Brust disposed of 351,001 shares of Class A Common Stock to satisfy tax withholding obligations.

General Counsel Kurt Oreshack sold 50,000 shares of Maravai LifeSciences Holdings, Inc. under a pre-established 10b5-1 trading plan.

Maravai LifeSciences Director Gregory T. Lucier transferred 46,293 shares of Class A Common Stock to a family partnership.

Maravai LifeSciences announces its 2026 Annual Meeting of Shareholders to be held virtually on May 26, 2026.

Maravai LifeSciences Holdings will hold its 2025 Annual Meeting of Shareholders virtually on May 22, 2025, to vote on director elections, auditor ratification, and executive compensation.

Maravai LifeSciences Holdings will hold its 2024 Annual Meeting of Shareholders virtually on May 23, 2024, to vote on director elections, auditor ratification, executive compensation, and other business.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has filed a Schedule 13G, reporting beneficial ownership of 4.7% of Maravai LifeSciences Holdings, Inc. Class A Common Stock.

12 West Capital Management LP and Joel Ramin have disclosed a beneficial ownership of 4.9% of Maravai LifeSciences Holdings, Inc. Class A Common Stock.

Several entities and individuals have collectively increased their beneficial ownership of Maravai LifeSciences Holdings, Inc. Class A Common Stock to over 9.21%.

Millennium Management LLC and associated entities have filed a Schedule 13G indicating their beneficial ownership of Maravai LifeSciences Holdings, Inc. has fallen below the 5% threshold.

12 West Capital Management LP and Joel Ramin have increased their beneficial ownership in Maravai LifeSciences Holdings, Inc. to 6.2% of Class A Common Stock.

A group of investors, including Stuart Feldman, Matthew Barkoff, and Joshua Wool, along with associated entities, reported a collective beneficial ownership of 7.23% in Maravai LifeSciences Holdings, Inc. Class A Common Stock.